Psoriasis is a pretty ugly skin disease that usually appears when we are facing great levels of stress, fatigue and chaos in our minds and day to day routine. It appears and disappears on regular basis and by now, an all-encompassing cure for the disease hasn’t been delivered. A new drug shows rapid improvements in patients with psoriasis, as it resulted from a trial performed by a team of researchers from University of Manchester.
The successful research, development and analysis has tested 2500 people with psoriasis. They were split in two groups, one of which has benefited from the treatment with ixekizumab, the new drug that showed immediate results. The other half were given a placebo or a popular drug for psoriasis cases, called etanercept.
Based on extensive tests and analysis, the new drug had beneficial effects for 40% of study subjects. They have showed complete recovery from psoriatic plaques after only 2 weeks of treatment. More than 90% of the people undergoing treatment have been showing serious improvements.
The first half of study subjects, namely the ones who were given ixekizumab, showed rapid and extensive improvements in conditions, compared with the other group that had no relevant signs of improvement.
No less than a month takes for the new drug to take action and kill the psoriasis bacteria. 71% of patients had shown a high level of improvement after the four weeks of treatment, being measured by a scale known under the name of Psoriasis Area and Severity Index.
Psoriasis affects 3% of people in UK and is characterized by an abundance of skin cells that cause raised bumps also known as “plaques”, growing on the skin. And it’s not only a question of unpleasant appearance, it is also very uncomfortable, flaky and itchy for the ones who suffer from it.
Current treatments don’t manage to act very efficiently on the disease, although there is a great range of medication on the market. From topical creams and shampoos, to Ultra-Violet light therapy, the variety comes to meet the needs of psoriasis patients, but at a low level of efficiency.
Ixekizumab is a cloned antibody that neutralizes the inflammatory effects of a protein in the skin that carries signals to cells. Interleukin is the virus that causes psoriasis, but with the help of medication such as Ixekizumab, the action of this bacteria is suppressed and effects of the disease slowly disappear with time.
Image Source: yahoo.com